ABSTRACT
BACKGROUND/AIMS: The current study examines the expression of molecular biomarkers in hepatocellular carcinoma (HCC) and whether these findings correlate with the clinicopathologic features of the disease and patient survival. METHODS: We analyzed the immunohistochemical expression of p53, mammalian target of rapamycin (mTOR), c-Met, and insulin-like growth factor 1 receptor (IGF-1R) heat shock protein 70 (HSP70) with the clinicopathologic features of 83 HCCs. RESULTS: p53 expression was higher in the male patients with undifferentiated histological tumor grades, cirrhosis, and portal vein invasion. High 48 c-Met expression correlated with cirrhosis, and high mTOR expression correlated with the tumor grade and cirrhosis. High IGF-1R expression correlated with the tumor grade and cirrhosis. A multivariate analysis identified a significant relationship between the high expression of p53, tumor grade, and portal vein invasion. In addition, a high expression of mTOR was related to tumor grade and cirrhosis, and a high expression of HSP70 was related to portal vein invasion in a multivariate analysis. The Kaplan-Meier survival curve for patients with high versus low Edmondson grades and p53 expression was statistically significant. CONCLUSIONS: p53, mTOR, and IGF-1R expression correlated with the Edmondson tumor grade in a univariate analysis, while p53 and mTOR correlated with the Edmondson tumor grade in a multivariate analysis. In addition, the tumor grade was found to predict survival. p53 was primarily related to the clinicopathologic features compared to other markers, and it is a poor prognostic factor of survival.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Carcinoma, Hepatocellular/metabolism , Disease-Free Survival , HSP70 Heat-Shock Proteins/metabolism , Liver Neoplasms/metabolism , Prognosis , Proto-Oncogene Proteins c-met/metabolism , Receptor, IGF Type 1/metabolism , Retrospective Studies , Risk Factors , TOR Serine-Threonine Kinases/metabolism , Treatment Outcome , Biomarkers, Tumor/metabolism , Tumor Suppressor Protein p53/metabolismABSTRACT
It has been demonstrated that resistance exercise improves cognitive functions in humans. Thus, an animal model that mimics this phenomenon can be an important tool for studying the underlying neurophysiological mechanisms. Here, we tested if an animal model for resistance exercise was able to improve the performance in a hippocampus-dependent memory task. In addition, we also evaluated the level of insulin-like growth factor 1/insulin growth factor receptor (IGF-1/IGF-1R), which plays pleiotropic roles in the nervous system. Adult male Wistar rats were divided into three groups (N = 10 for each group): control, SHAM, and resistance exercise (RES). The RES group was submitted to 8 weeks of progressive resistance exercise in a vertical ladder apparatus, while the SHAM group was left in the same apparatus without exercising. Analysis of a cross-sectional area of the flexor digitorum longus muscle indicated that this training period was sufficient to cause muscle fiber hypertrophy. In a step-through passive avoidance task (PA), the RES group presented a longer latency than the other groups on the test day. We also observed an increase of 43 and 94% for systemic and hippocampal IGF-1 concentration, respectively, in the RES group compared to the others. A positive correlation was established between PA performance and systemic IGF-1 (r = 0.46, P < 0.05). Taken together, our data indicate that resistance exercise improves the hippocampus-dependent memory task with a concomitant increase of IGF-1 level in the rat model. This model can be further explored to better understand the effects of resistance exercise on brain functions.
Subject(s)
Animals , Male , Avoidance Learning/physiology , Hippocampus/physiology , Memory/physiology , Physical Conditioning, Animal/physiology , Resistance Training , Hippocampus/metabolism , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/metabolism , Rats, Wistar , Receptor, IGF Type 1/blood , Receptor, IGF Type 1/metabolismABSTRACT
El factor de crecimiento análogo a insulina tipo 1 (IGF-1) es un péptido relacionado estructural y funcionalmente con insulina que posee efectos mitogénicos y citoprotectores. Sus efectos biológicos dependen de la activación del receptor de IGF- 1 (IGF-1R), perteneciente a la familia de receptores con actividad tirosina kinasa intrínseca y que se localiza en la superficie celular. IGF-1 es el principal mediador fisiológico de la hormona del crecimiento y dado que su gen se expresa en múltiplestejidos, este factor es clave en la comunicación endocrina, paracrina y autocrina. Recientes evidencias muestran que IGF- 1 ejerce variadas acciones pleiotrópicas en el sistema cardiovascular, destacándose sus efectos en la hipertrofia, muerte y regeneración celular. En el corazón, IGF-1 promueve su crecimiento, mejora su contractibilidad, facilita el metabolismode la glucosa, disminuye el nivel de insulina circulante, aumenta la sensibilidad a esta hormona, estabiliza el perfil lipídico y estimula la regeneración del músculo cardíaco. Evidencias clínicas y experimentales han mostrado que el deterioro de la función cardíaca se asocia a bajos niveles circulantes de IGF-1. Alteraciones tanto en los niveles de IGF-1 como en su sistema transduccional se consideran factores de riesgo para el desarrollo de distintas patologías cardíacas. Todosestos antecedentes destacan el papel del IGF-1 en cardioprotección y su potencialidad para el tratamiento de diversas patologías cardiovasculares. Sin embargo, los mecanismos moleculares implicados en estos efectos prácticamente se desconocen. En esta revisión, junto con entregar antecedentes actualizados y críticos de las acciones cardiovasculares del IGF-1, se proyectan sus aplicaciones terapéuticas.
Subject(s)
Humans , Cardiotonic Agents/pharmacology , Cardiovascular Diseases/prevention & control , Receptor, IGF Type 1/metabolism , Receptor, IGF Type 1/therapeutic useABSTRACT
We addressed the effect of targeting type I insulin-like growth factor receptor (IGF-IR), with antisense strategies in in vivo growth of breast cancer cells. We used C4HD tumors from an experimental model of hormonal carcinogenesis in which medroxyprogesterone acetate induced mammary adenocarcinomas in Balb/c mice. Intratumor or systemic administration of phosphorothiolated antisense oligodeoxynucleotides (AS[S]ODN) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. The antitumor effect was specific since inhibition of tumor growth was dose-dependent and no effect was observed in mice treated with sense S[S]ODN. Tumors from AS[S]ODN-treated mice showed a decrease in IGF-IR expression and in insulin receptor substrate-1 tyrosine phosphorylation. Activation of PI-3K/Akt, p42/p44 MAPK and ErbB-2 was abolished in tumors treated with AS[S]ODN. Progesterone receptor expression or activity remained invariable. This is the first demonstration that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S]ODN.
Evaluamos el efecto del bloqueo de la expresión del receptor del factor de crecimiento semejante a lainsulina tipo I (IGF-IR) sobre el crecimiento in vivo de cáncer de mama empleando una estrategiaantisentido. Utilizamos el adenocarcinoma mamario murino progestágeno-dependiente C4HD. La administración intratumoral o sistémica de oligodeoxinucleótidos antisentido fosfotiolados al ARNm del IGF-IR (AS[S]ODN) inhibió el crecimiento tumoral. El efecto antitumoral fue específico debido a su dosis-dependencia y a la faltade efecto en ratones tratados con el S[S]ODN sentido. Los tumores obtenidos de ratones tratados con AS[S]ODN mostraron: disminución en la expresión de IGF-IR y en la fosforilación del sustrato del receptor de insulina-1, inhibición de la activación de PI-3K/Akt, p42/p44MAPK y ErbB-2, mientras que la expresión y activación del receptor de progesterona no se afectó. Es la primera demostración que el